麗珠醫藥(01513.HK)旗下重組新型冠狀病毒融合蛋白二價疫苗獲批臨床試驗

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

麗珠醫藥(01513.HK)旗下重組新型冠狀病毒融合蛋白二價疫苗獲批臨床試驗

阿思達克 07-18 09:28

麗珠醫藥(01513.HK)公布，近日控股附屬珠麗珠單抗收到國家藥監局核准簽發的《藥物臨床試驗批件》，應急批准麗珠單抗研發的「重組新型冠狀病毒融合蛋白二價(原型株/Omicron XBB 變異株)疫苗(CHO細胞)」進行臨床試驗。公開信息顯示，截至目前，國內已獲批使用的新冠疫苗共有16款，其中包括5款滅活疫苗、7款重組蛋白疫苗、2款腺病毒載體疫苗、1款流感病毒載體疫苗、1款mRNA疫苗。

麗珠醫藥(01513.HK)

Relevant Stocks

麗珠醫藥(01513.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

麗珠醫藥(01513.HK)旗下重組新型冠狀病毒融合蛋白二價疫苗獲批臨床試驗

Services

About Us

Agreement Statement